

1 TITLE: Development and use of a method based on the anti-N reactivity of longitudinal  
2 samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated population

3

4 RUNNING HEAD: Novel method for SARS-CoV-2 prevalence

5

6 AUTHORS: Renée Bazin<sup>1\*</sup>, Samuel Rochette<sup>2</sup>, Josée Perreault<sup>1</sup>, Marie-Josée Fournier<sup>1</sup>,  
7 Yves Grégoire<sup>1</sup>, Amélie Boivin<sup>2</sup>, Antoine Lewin<sup>2,3</sup>, Marc Germain<sup>1</sup>, Christian Renaud<sup>2,4</sup>

8 <sup>1</sup>Affaires Médicales et Innovation, Héma-Québec, Québec, QC, Canada, G1V 4C3

9 <sup>2</sup>Affaires Médicales et Innovation, Héma-Québec, Montréal, QC, Canada, H4R 2W7

10 <sup>3</sup>Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke,  
11 QC, Canada, J1K 2R1

12 <sup>4</sup>Département de microbiologie, CHU Sainte-Justine, Université de Montréal, Montréal,  
13 QC, Canada, H3T 1C5

14

15 \*CORRESPONDING AUTHOR

16 Renée Bazin, PhD

17 Scientific Director, Medical Affairs and Innovation, Héma-Québec

18 1070 Ave des Sciences-de-la-Vie, Québec, QC Canada G1V 5C3

19 Phone: +1 418 780 4362 ext 3234; Fax: +1 418 780 2091

20 Email: [renee.bazin@hema-quebec.qc.ca](mailto:renee.bazin@hema-quebec.qc.ca)

21

22 WORD COUNT: Abstract, 197; Main text, 1906.

23 **FOOTNOTES**

24

25 CONFLICT OF INTEREST: The authors have no conflict of interest to declare.

26

27 FUNDING: This work was supported by the Ministère de la Santé et des Services Sociaux  
28 (MSSS) du Québec and the Public Health Agency of Canada (through the Reference Group  
29 on the Surveillance of vaccines and the COVID-19 Immunity Task Force). The views  
30 expressed here do not necessarily reflect those of the MSSS and Public Health Agency of  
31 Canada.

32

33 CORRESPONDANCE AND REQUEST FOR REPRINTS:

34 Renée Bazin, PhD

35 Scientific Director, Medical Affairs and Innovation, Héma-Québec

36 1070 Ave des Sciences-de-la-Vie, Québec, QC Canada G1V 5C3

37 Phone: +1 418 780 4362 ext 3234; Fax: +1 418 780 2091

38 Email: [renee.bazin@hema-quebec.qc.ca](mailto:renee.bazin@hema-quebec.qc.ca)

39 **ABSTRACT**

40 *Background:* Emerging evidence suggests that COVID-19 vaccination decreases the  
41 sensitivity of anti-nucleocapsid (N) serologies, making them less reliable to assess  
42 recently-acquired infections. We therefore developed and tested a new approach based on  
43 the ratio of the anti-N absorbance of longitudinal samples to overcome this limitation.

44 *Methods:* Previously vaccinated repeat plasma donors provided at least one pre-infection  
45 (reference) and one post-infection (test) sample. All samples were tested using an in-house  
46 anti-N ELISA. Seropositivity was determined based on the ratio between the anti-N  
47 absorbance of the test and reference samples. The ratio approach was tested in a real-world  
48 setting during three cross-sectional serosurveys carried out among plasma donors in  
49 Québec, Canada.

50 *Results:* Using a cut-off ratio of 1.5, the approach had a sensitivity of 95.2% among the  
51 248 previously vaccinated and infected donors compared with 63.3% for the conventional  
52 approach. When tested in a real-world setting, the ratio-based approach yielded an adjusted  
53 seroprevalence of 27.4% (95% confidence interval [CI]=23.8%-30.9%) at the latest time  
54 point considered, compared to 15.1% (95% CI=12.2%-18.0%) for the conventional  
55 approach.

56 *Conclusions:* This article describes a new and highly-sensitive approach that captures a  
57 significantly greater proportion of vaccinated individuals with a recent history of SARS-  
58 CoV-2 infection.

59

60 **KEYWORDS:** COVID-19; Serosurvey; Anti-nucleocapsid; Vaccination; Absorbance ratio

## 61 **BACKGROUND**

62 Since the beginning of the SARS-CoV-2 pandemic, serosurveys have been key to public  
63 health decision-making, but their conduct and interpretation have become more  
64 challenging. Seroprevalence may no longer be viewed as an indicator of progression to a  
65 putative state of herd immunity — a prospect that looks increasingly dim with the continual  
66 emergence of immune-escape variants.[1,2] Early serosurveys assessed anti-spike (S) or  
67 anti-receptor binding domain (RBD) seropositivity in vaccine-naïve individuals, but this  
68 approach cannot disentangle infection- from vaccine-induced seropositivity in vaccinated  
69 individuals. Anti-nucleocapsid (N) seroprevalence was initially viewed as a solution to this  
70 challenge but is more affected by seroreversion than anti-S or anti-RBD seroprevalence,[3–  
71 12] thus leading to declining or stagnating seroprevalence estimates despite rising case  
72 counts.[3,13,14] What is more, emerging evidence suggests that vaccination hinders the  
73 sensitivity of conventional anti-N assays. In a study of 4000 fully vaccinated health care  
74 workers, 23 experienced a breakthrough infection, but only six (26%) were seropositive  
75 for anti-N.[15] More recently, a study of COVE (i.e., mRNA-1273 vs. placebo to prevent  
76 COVID-19) participants with a confirmed history of SARS-CoV-2 breakthrough infection  
77 found that only 40.4% of vaccine recipients were seropositive for anti-N, as compared with  
78 93.4% among placebo recipients.[16] Although preliminary, this evidence is worrisome as  
79 it may invalidate conventional anti-N assays as a marker of SARS-CoV-2 infections,  
80 leaving few alternatives to assess the progression of the pandemic.

81 The reduced rate of anti-N seroconversion among vaccinated individuals might be  
82 explained by reduced exposure to the N antigen following infection,[16] which may lead  
83 to anti-N levels that do not pass the seropositivity threshold of conventional anti-N assays.

84 We postulated that this limitation could be addressed by comparing the anti-N levels of  
85 samples collected at different time points, thus enabling the detection of meaningful signal  
86 increases in response to recently acquired infections. Based on this premise, we sought to  
87 develop and test an empirical approach to overcome the issue of vaccination in anti-N  
88 serosurveys.

89

## 90 **METHODS**

### 91 *Donors*

92 The approach was developed and tested based on longitudinally collected plasma samples  
93 from regular plasma donors who consented to participate in a COVID-19-dedicated  
94 biobank in Québec, Canada (“PlasCov”; see **Supplementary Methods** for details on the  
95 biobank). The PlasCov biobank and the use of samples for the present study were approved  
96 by the Héma-Québec Research Ethics Board. To develop the approach, plasma samples  
97 from donors who met the following criteria were selected: (1) received  $\geq 1$  vaccine dose  
98 against SARS-CoV-2; (2) had a PCR-confirmed SARS-CoV-2 infection between  
99 12/15/2021 and 03/20/2022 (i.e., during the Omicron wave); and (3) made  $\geq 2$  donations:  
100 one before — but as close as possible — to 12/15/2021 (i.e., the reference sample collected  
101 before the Omicron wave) and one between 01/02/2022 and 04/20/2022 after the confirmed  
102 infection (i.e., the test sample collected during the Omicron wave; see **Supplementary**  
103 **Methods** for other inclusion criteria). To test the approach in a real-world setting, we  
104 conducted three cross-sectional serosurveys in Québec (Canada) that included plasma  
105 donors who made  $\geq 1$  donation in one of the following periods (all during the Omicron  
106 wave): 01/17/2022-01/18/2022, 02/14/2022-02/15/2022, and 03/16/2022-03/18/2022 (see  
107 **Supplementary Methods** for other inclusion criteria). All of these donors were included  
108 in the analysis conducted with the conventional approach, and only those with  $\geq 1$  reference  
109 sample and  $\geq 1$  test sample were included in the analysis conducted with the new ratio-  
110 based approach (described further down).

### 111 *Anti-N ELISA*

112 All samples used to develop and test the ratio-based approach were analysed for anti-N  
113 seropositivity using an in-house developed conventional anti-N ELISA. The assay was  
114 similar to a previously described anti-RBD assay,[17] except that the recombinant N  
115 antigen (Centre National en Électrochimie et en Technologies Environnementales Inc.,  
116 Shawinigan, Canada) was used (0.25 µg/ml) in lieu of the RBD antigen (2.5 µg/ml). This  
117 assay has a sensitivity of 98.5% and a specificity of 98.1% among unvaccinated and  
118 recently infected individuals using an absorbance cut-off value of 0.350 (see  
119 **Supplementary Methods** for details).

#### 120 *Ratio-based approach to determine anti-N seropositivity*

121 The herein described ratio-based approach determines anti-N seropositivity based on the  
122 ratio between the absorbances of the test and reference samples (anti-N ratio). The  
123 positivity cut-off for the anti-N ratio was selected based on the proportion of vaccinated  
124 donors with a prior confirmed infection being captured (i.e., sensitivity). A baseline  
125 threshold was applied to exclude samples with low absorbance values (i.e., falling in the  
126 assay's background noise) and hence reduce false positives resulting from the technical  
127 variability of the assay. Donors for whom the test sample had an absorbance value below  
128 this threshold were considered seronegative and no ratio was calculated.

#### 129 *Statistical analysis*

130 Seroprevalence estimates were reported along with binomial proportion confidence  
131 intervals (CI) after adjusting for age, sex, and regional distribution (based on 2011 census  
132 data) for both cumulative and ratio-based approaches.

## 133 RESULTS

### 134 *Development of the ratio-based approach*

135 The approach was developed using 248 vaccinated donors with a PCR-confirmed infection  
136 during the Omicron wave (mean age: 40.6 years; females: 48.3%), including 246 (99.2%)  
137 who had received  $\geq 2$  vaccine doses before their infection. The median interval between the  
138 PCR result and the collection of the test sample was 31 days (interquartile range: 19-46  
139 days).

140 The target sensitivity of the ratio-based approach was 95%, as recommended by national  
141 regulatory authorities.[18] A sensitivity  $> 95\%$  was achieved with anti-N ratios of up to 1.5  
142 and dropped abruptly at higher ratios (**Figure 1**). Therefore, a positivity cut-off of 1.5 was  
143 selected.

144 To improve the specificity of the approach, we determined a limit of absorbance below  
145 which a test sample would not be included since low absorbance values are more variable  
146 and may inadvertently produce anti-N ratios  $\geq 1.5$  owing to the technical variability of the  
147 assay. Indeed, the coefficient of variation of 38 technical replicates of a negative control  
148 sample (pre-pandemic plasma pool) was 12.4% with a mean absorbance of 0.121. We  
149 therefore conservatively selected 0.100 for this lower limit of absorbance in test samples.

150 Applying the above-mentioned thresholds, the sensitivity of the ratio-based approach to  
151 identify new infections was estimated at 95.2% (236/248), whereas that of the conventional  
152 approach (based on the 0.350 seropositivity cut-off of the anti-N ELISA at the post-  
153 infection time point) was 63.3% (157/248).



154 The stability of the baseline anti-N signal in reference samples was assessed among seven  
155 donors with an anti-N ratio  $\geq 1.5$  and three reference samples. For these donors, the anti-N  
156 signal of the reference samples had a mean coefficient of variation (CV) of 10.7% (**Figure**  
157 **2**), and all had an anti-N ratio  $\geq 1.5$  regardless of the reference sample considered. The  
158 analysis of an additional 12 donors with 2 reference samples confirmed the low variability  
159 of the baseline anti-N signal, with a mean CV of 8.4% (data not shown). False positives  
160 due to an unstable anti-N signal in reference samples thus appear to be infrequent, although  
161 a larger sample would be needed to better estimate this rate.

### 162 *Testing the ratio-based approach in a real-world setting*

163 The ratio-based approach was tested through a serosurvey that included 1618 plasma  
164 donors (mean age=54.0 years; females=32.8%) who donated during the Omicron wave, of  
165 which 1519 (93.9%) were included in the analysis conducted with the ratio-based  
166 approach. Using the ratio-based approach, the adjusted seroprevalence was 9.7% (95%  
167 CI=7.1%-12.4%) for the period that covered the beginning of the Omicron wave up until  
168 01/17/2022-01/18/2022, 20.3% (95% CI=16.8%-23.8%) for that up until 02/14/2022-  
169 02/15/2022, and 27.4% (95% CI=23.8%-30.9%) up until 03/16/2022-03/18/2022. Using  
170 the conventional approach, the adjusted seroprevalence was 8.3% (95% CI=6.0%-10.5%)  
171 for samples collected between 01/17/2022 and 01/18/2022, 14.3% (95% CI=11.3%-17.4%)  
172 between 02/14/2022 and 02/15/2022, and 15.1% (95% CI=12.2%-18.0%) between  
173 03/16/2022 and 03/18/2022 (**Figure 3**).

## 174 **DISCUSSION**

175 This study presents a new approach (ratio-based approach) to assess the seroprevalence  
176 during a period of interest. The approach relies on longitudinally collected samples and  
177 determines seropositivity based on the difference between the result of a test sample and  
178 that of a reference sample collected earlier. In samples collected before and during the  
179 Omicron wave of the SARS-CoV-2 pandemic, the approach had a sensitivity of 95.2%  
180 among vaccinated individuals who had a breakthrough infection, which favorably  
181 compares with the sensitivity of 63.3% obtained with the conventional approach.  
182 Furthermore, at the latest time point considered in our analysis, this new approach  
183 estimated the adjusted anti-N seroprevalence at 27.4% during the Omicron wave, whereas  
184 this estimate was only 15.4% with the conventional single-sample approach. The  
185 conventional approach, as used in most (if not all) serosurveys, thus substantially  
186 underestimated the seroprevalence of anti-N antibodies in vaccinated individuals, even  
187 though it should theoretically reflect past infections since the onset of the pandemic,  
188 whereas the ratio-based approach measures seroprevalence only during a defined period of  
189 interest (the Omicron wave in the present study).

190 In addition to providing a high sensitivity, a cut-off of 1.5 for the anti-N ratio seemed  
191 adequate to reduce false positives that may arise due to the technical variability of the  
192 ELISA. The CV of negative controls (n=38 technical replicates) was 12.4%, and that of  
193 positive controls (n=38 technical replicates) was 11.3%, suggesting a cut-off lower than  
194  $\sim 1.3$  (i.e.,  $[100\%+12\%]/[100\%-12\%]$ ) would be inadequate owing to the assay's technical  
195 variability. The selected cut-off thus probably represents a good compromise between  
196 sensitivity and technical false positives.

197 The sensitivity of the conventional approach (63.3%) was higher than that reported in  
198 previous studies for vaccinated individuals (26.0%-40.4%).[15,16] Besides differences  
199 among assays, this discrepancy may be explained by the fact that the Omicron variant (for  
200 which vaccine efficacy is lower) was dominant during our study, whereas earlier variants  
201 (for which vaccine efficacy is higher) were dominant in previous studies.[19–22] As a  
202 result, individuals included in our study may have been exposed to higher viral loads than  
203 those included in previous studies, thereby increasing the likelihood of anti-N  
204 seroconversion.

205 The ratio-based approach estimated the adjusted anti-N seroprevalence at 27.4% during a  
206 period that covered the Omicron wave up until mid-March 2022. This figure is consistent  
207 with a recent modeling study, which estimated at 32% the proportion of Montreal residents  
208 who contracted SARS-CoV-2 between 12/01/2021 and 02/21/2022.[23] By contrast, the  
209 conventional approach estimated the adjusted anti-N seroprevalence at 15.1% in mid-  
210 March 2022. Together with the sensitivity data described above, these results demonstrate  
211 the extent to which the ratio-based approach captures a larger share of infections than the  
212 conventional approach.

213 This study has a few limitations. To begin, the true specificity of the ratio-based approach  
214 could not be assessed because of the unavailability of longitudinal samples from  
215 individuals ascertained not to have a history of SARS-CoV-2 infection (e.g., pre-pandemic  
216 longitudinal samples). However, the approach accounts for technical false positives by  
217 specifying a lower limit of absorbance below which test samples cannot be considered  
218 positive. In addition, the ratio-based approach requires access to at least 2 relatively recent  
219 samples per individual, which limits the pool of individuals that can be included in the

220 analyses. Furthermore, the plasma donors who participated in PlasCov may not be  
221 representative of the general population. These individuals are generally healthier[24] and  
222 more of them are vaccinated against COVID-19 compared with the general population.  
223 Lastly, the legal age for plasma donation is 18 or older, and so children were not included  
224 in this study.

225

## 226 **CONCLUSION**

227 This article describes a new and highly-sensitive approach (ratio-based approach) that  
228 successfully addresses the issue of vaccination in serosurveys. Relative to the conventional  
229 approach, the ratio-based approach captured a significantly greater proportion of  
230 vaccinated individuals with a recent history of SARS-CoV-2 infection (i.e., 95.2% vs.  
231 63.3%). When tested in a real-world setting, this new approach also yielded a significantly  
232 higher anti-N seroprevalence than the conventional approach (i.e., 27.4% vs. 15.4%).

233

234

235 **ACKNOWLEDGMENTS**

236 The authors thank all the plasma donors who participate in the PlasCov biobank and the  
237 Héma-Québec personnel involved in sample collection and recovery from the biobank's  
238 inventory.

239 **REFERENCES**

- 240 1. Aschwanden C. Five reasons why COVID herd immunity is probably impossible.  
241 Nature **2021**; 591:520–522.
- 242 2. Barber RM, Sorensen RJ, Pigott DM, et al. Estimating global, regional, and national  
243 daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a  
244 statistical analysis. The Lancet **2022**; 399:2351-2380.
- 245 3. Bolotin S, Tran V, Osman S, et al. SARS-CoV-2 seroprevalence survey estimates  
246 are affected by anti-nucleocapsid antibody decline. J Infect Dis **2021**; 223:1334–  
247 1338.
- 248 4. Whitcombe AL, McGregor R, Craigie A, et al. Comprehensive analysis of SARS-  
249 CoV-2 antibody dynamics in New Zealand. Clin Transl Immunol **2021**; 10:e1261.
- 250 5. Carreño JM, Mendu DR, Simon V, et al. Longitudinal analysis of severe acute  
251 respiratory syndrome coronavirus 2 seroprevalence using multiple serology  
252 platforms. Iscience **2021**; 24:102937.
- 253 6. Gallais F, Gantner P, Bruel T, et al. Evolution of antibody responses up to 13  
254 months after SARS-CoV-2 infection and risk of reinfection. EBioMedicine **2021**;  
255 71:103561.
- 256 7. Nunhofer V, Weidner L, Hoeggerl AD, et al. Persistence of Naturally Acquired and  
257 Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection.  
258 Viruses **2022**; 14:637.

- 259 8. Fedele G, Stefanelli P, Bella A, et al. Anti-SARS-CoV-2 antibodies persistence after  
260 natural infection: a repeated serosurvey in Northern Italy: COVID-19 IgG longevity  
261 and neutralization. *Ann Ist Super Sanita* **2021**; 57:265–271.
- 262 9. Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 spike versus  
263 nucleoprotein antibody responses impact the estimates of infections in population-  
264 based seroprevalence studies. *J Virol* **2021**; 95:e01828-20.
- 265 10. Grandjean L, Saso A, Torres Ortiz A, et al. Long-Term Persistence of Spike Protein  
266 Antibody and Predictive Modeling of Antibody Dynamics After Infection With  
267 Severe Acute Respiratory Syndrome Coronavirus 2. *Clin Infect Dis* **2021**; 74:1220-  
268 1229.
- 269 11. Pilmis B, Elkaibi I, Ponfilly GP de, et al. Evolution of anti-SARS-CoV-2 immune  
270 response in a cohort of French healthcare workers followed for 7 months. *Infect Dis*  
271 *Now* **2022**; 52:68-74.
- 272 12. Lee CC, Segaloff HE, Cole D, et al. A cohort study measuring SARS-CoV-2  
273 seroconversion and serial viral testing in university students. *BMC Infect Dis* **2022**;  
274 22:1–11.
- 275 13. Jones JM, Stone M, Sulaeman H, et al. Estimated US infection-and vaccine-induced  
276 SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021.  
277 *JAMA* **2021**; 326:1400–1409.
- 278 14. Siller A, Seekircher L, Wachter GA, et al. Seroprevalence, Waning and Correlates  
279 of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of

- 280 35,193 Blood Donors Conducted between June 2020 and September 2021. *Viruses*  
281 **2022**; 14:568.
- 282 15. Allen N, Brady M, Martin AIC, et al. Serological markers of SARS-CoV-2  
283 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of  
284 natural infection in vaccinated individuals. *J Infect* **2021**; 83:e9–e10.
- 285 16. Follmann D, Janes HE, Buhule OD, et al. Anti-nucleocapsid antibodies after SARS-  
286 CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-  
287 1273 COVID-19 vaccine efficacy clinical trial. *Ann Intern Med*. Jul 5, 2022.  
288 Available from: [https://doi: 10.7326/M22-1300](https://doi.org/10.7326/M22-1300).
- 289 17. Perreault J, Tremblay T, Fournier M-J, et al. Waning of SARS-CoV-2 RBD  
290 antibodies in longitudinal convalescent plasma samples within 4 months after  
291 symptom onset. *Blood* **2020**; 136:2588-2591.
- 292 18. Government of Canada. COVID-19 serological testing devices: Notice on  
293 sensitivity and specificity values [Internet]. [cited 2022 Jun 17]. Available from:  
294 [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/serological/notice-sensitivity-specificity-values.html)  
295 [industry/medical-devices/testing/serological/notice-sensitivity-specificity-](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/serological/notice-sensitivity-specificity-values.html)  
296 [values.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/serological/notice-sensitivity-specificity-values.html)
- 297 19. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters  
298 against SARS-CoV-2 omicron infection in Qatar. *N Engl J Med* **2022**; 386:1804–  
299 1816.



- 300 20. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of  
301 mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2  
302 Omicron and Delta variants. *Jama* **2022**; 327:639–651.
- 303 21. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273  
304 SARS-CoV-2 vaccine. *N Engl J Med* **2020**; 384:403-416.
- 305 22. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2  
306 mRNA Covid-19 vaccine. *N Engl J Med* **2020**; 383:2603-2615.
- 307 23. Brisson, M, Hardy, M, Gingras, G, Drolet, M, Laprise, JF. Modélisation de l’impact  
308 potentiel des assouplissements des mesures sanitaires sur l’évolution de la COVID-  
309 19 dans le Grand Montréal [Internet]. [cited 2022 Apr 13]. Available from:  
310 [https://marc-brisson.net/covid19-response/Modelisation-evolution-COVID-19-au-](https://marc-brisson.net/covid19-response/Modelisation-evolution-COVID-19-au-Quebec_Rapport19_2-mars-2022.pdf)  
311 [Quebec\\_Rapport19\\_2-mars-2022.pdf](https://marc-brisson.net/covid19-response/Modelisation-evolution-COVID-19-au-Quebec_Rapport19_2-mars-2022.pdf)
- 312 24. Golding J, Northstone K, Miller LL, Davey Smith G, Pembrey M. Differences  
313 between blood donors and a population sample: implications for case–control  
314 studies. *Int J Epidemiol* **2013**; 42:1145–1156.

## FIGURE LEGENDS

**Figure 1. Sensitivity of detection of seropositive individuals captured using various anti-N ratio.** The ratio of the anti-N signal between the test and reference samples was calculated. The sensitivity of detection obtained for ratios between 0.5 and 2.8 is shown. Sensitivity below the target value of 95% is indicated by the grey area.

**Figure 2: Stability of the anti-N signal in reference samples.** Results of the anti-N ELISA for 7 individuals with three reference (pre-infection) samples. Day 0 represents the collection of the first reference sample; the interval (in days) between the collection of the first sample and the other samples is shown on the  $x$  axis. The first 3 dots on each panel show the results of reference samples and the last dot shows the result of the post-infection sample. The coefficient of variation of the results for the 3 reference samples is indicated on each graph.

**Figure 3. Adjusted seroprevalence obtained with the conventional and ratio-based approaches.** The adjusted seroprevalence (age, sex, and regional distribution of the participants) was calculated using the ratio-based approach with samples covering 3 time intervals: A-C) since date of reference sample collection up to A) 17-18 January 2022, B) 14-15 February 2022 or C) 16-18 March 2022. The adjusted seroprevalence was also calculated using the conventional approach with samples collected at 3 different time points: A) 17-18 January 2022; B) 14-15 February 2022; C) 16-18 March 2022. The shaded areas around the lines represent the 95% confidence intervals of the seroprevalence estimates.

**FIGURE 1**





FIGURE 2



**FIGURE 3**

